# Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients

> **NCT00574743** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 162 (actual)

## Conditions studied

- Heart Transplantation

## Interventions

- **DRUG:** Enteric-coated Mycophenolate Sodium

## Key facts

- **NCT ID:** NCT00574743
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2004-04
- **Final completion:** —
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2011-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00574743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00574743, "Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00574743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*